Clinical Trials Browser

Phase 2 × NSCLC × S 1 (combination) × Clear all

NCT05773092 2025-09-03

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Phase 2 Active not recruiting

NSCLC

NCT02631460 2015-12-16

S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

Phase 2 Unknown

NSCLC